PI3Kδ Inhibition Potentiates Glucocorticoids in B-lymphoblastic Leukemia by Decreasing Receptor Phosphorylation and...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Glucocorticoids are essential for B-lymphoblastic leukemia (B-ALL) treatment.
• Enhancing glucocorticoid efficacy is crucial for improving patient outcomes.
• Previous research indicated that idelalisib, a PI3Kδ inhibitor, boosts glucocorticoid activity in B-ALL cells.

Purpose of the Study:

• To investigate the potentiation effect of idelalisib on glucocorticoid efficacy in B-ALL.
• To elucidate the molecular mechanisms underlying this enhanced sensitivity.
• To assess the potential of this combination therapy for B-ALL treatment, including high-risk cases.

Main Methods:

• Testing idelalisib's effect on glucocorticoid potency in primary B-ALL specimens.
• Analyzing the regulation of glucocorticoid-responsive genes.
• Investigating the impact of idelalisib on glucocorticoid receptor (GR) phosphorylation at specific sites (S203, S226).
• Assessing GR DNA binding affinity in vitro after site-directed mutagenesis.

Main Results:

• Idelalisib enhanced glucocorticoid potency in 90% of primary B-ALL samples, particularly at sub-saturating doses.
• Potentiation correlated with improved regulation of glucocorticoid-induced genes, including those promoting cell death.
• Idelalisib reduced GR phosphorylation at S203 and S226; ablating these sites increased glucocorticoid sensitivity.
• Phosphorylation at S226 was shown to decrease GR DNA binding affinity.

Conclusions:

• PI3Kδ inhibition by idelalisib enhances glucocorticoid efficacy in B-ALL by reducing GR phosphorylation, increasing DNA binding, and improving gene regulation.
• This combination therapy is effective in most B-ALL patients, especially those with less responsive or high-risk disease.
• The idelalisib-glucocorticoid combination offers a promising strategy for developing less toxic, glucocorticoid-sparing therapies for B-ALL.